Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Inclusion Criteria: * Patients with histopathological or cytopathological diagnosis of advanced biliary carcinoma (gallbladder cancer, cholangiocarcinoma, ampullary cancer) not amenable to conventional surgical approach are eligible * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral CT scan * No patients with untreated brain metastases * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) * Life expectancy of greater than 12 weeks * White blood cell (WBC)/leukocytes ≥ 3,000/μL * Absolute neutrophil count ≥ 1,500/μL * Platelets ≥ 100,000/μL * Hemoglobin ≥ 9 g/dL * Total bilirubin ≤ 3 mg/dL * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) ≤ 2.5 times institutional upper limit of normal * Creatinine within normal institutional limits OR calculated creatinine clearance ≥ 60 mL/min * No patients with proteinuria not meeting the criteria below; urine sample must be tested by urine protein:creatinine (UPC) ratio or by urinalysis method within 1 week of starting study treatment; depending upon the testing method used, the following criteria must be met: * UPC ratio must be \< 1.0; if UPC ratio is ≥ 1.0, a 24-hour urine specimen must be collected and must dem…